This comparison examines three established healthcare stocks—Alcon (ALC), Medtronic (MDT), and Thermo Fisher Scientific (TMO)—to highlight differences in business models, recent price behavior, and positioning within the medical and life sciences sectors. The analysis draws on observable developments from recent market activity to provide traders and investors with a factual framework for evaluating relative performance. Portfolio managers seeking sector diversification, growth-oriented investors monitoring earnings catalysts, and traders assessing momentum shifts may find the comparison useful for understanding trade-offs across these names.
Alcon (ALC) develops and manufactures products for eye care, including surgical equipment and vision care solutions. In recent weeks, the company reported first-quarter 2026 results showing year-over-year revenue growth of approximately 10 percent to $2.7 billion, with core earnings per share (EPS) exceeding expectations. However, a modest revenue shortfall relative to forecasts and supply chain considerations triggered an immediate share price decline of roughly 10 percent following the release. Broader market activity since then has kept shares under pressure, with trading levels reflecting tempered sentiment around top-line execution despite margin improvements and a new share repurchase authorization.
Medtronic (MDT) provides a wide range of medical devices spanning cardiovascular, diabetes, and surgical technologies. Recent market activity shows the stock trading lower ahead of its scheduled fourth-quarter fiscal 2026 earnings report, with analysts projecting revenue growth near 8 percent but a modest year-over-year decline in EPS. Performance in recent weeks has been influenced by sector-wide caution and positioning below key moving averages, while the company maintains focus on portfolio expansion and procedural demand. Sentiment remains tied to execution on upcoming results and broader healthcare utilization trends.
Thermo Fisher Scientific (TMO) supplies life sciences instruments, diagnostics, and biopharma services. First-quarter 2026 results delivered revenue of $11.01 billion and adjusted EPS above consensus, supported by acquisitions and operational efficiency. Although organic growth appeared subdued, recent price action has turned positive, with shares recovering notably in the latest trading sessions amid improved market rotation into the sector. Performance reflects sensitivity to laboratory spending patterns and capital deployment initiatives, including share repurchases and dividend increases.
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance profiles. Only those demonstrating strong suitability for prevailing market conditions are featured in the trending section. Available bots display a range of historical win rates, average returns per trade, and drawdown statistics, allowing users to compare options across diverse trading styles. The platform provides transparent metrics on each bot’s track record to support informed evaluation. Review the Trending AI Robots page for current selections and detailed statistics.
Alcon (ALC), Medtronic (MDT), and Thermo Fisher Scientific (TMO) share healthcare sector exposure yet differ markedly in business models. ALC concentrates on ophthalmic surgical and vision products with recurring revenue elements from consumables. MDT offers broad medical device diversification, exposing it to procedure volumes across multiple specialties. TMO emphasizes tools and services for research and diagnostics, with greater sensitivity to biopharma capital expenditure and laboratory demand.
Recent momentum contrasts show TMO benefiting from post-earnings recovery, while ALC absorbed a sharper reaction to its quarterly update and MDT trades in anticipation of results. Valuation sensitivity appears higher for growth-oriented names like TMO during periods of organic slowdown, whereas ALC and MDT face scrutiny over margin sustainability and competitive pressures. Risk factors include supply chain variability for ALC, regulatory and reimbursement dynamics for MDT, and end-market spending cycles for TMO. Market sentiment across the group remains measured, balancing earnings resilience against macroeconomic influences on healthcare investment.
Based on observable factors such as recent price stabilization, earnings delivery consistency, and relative positioning within the healthcare space, Tickeron’s AI currently assigns a probabilistic edge to Thermo Fisher Scientific (TMO). The stock’s post-earnings rebound and ongoing capital deployment initiatives suggest steadier trend alignment compared with peers navigating immediate post-report volatility or pre-earnings caution. This assessment reflects pattern recognition across trend consistency and catalyst visibility rather than any guarantee of future outcomes.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 4 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s), and TMO’s TA Score reflects 4 bullish TA indicator(s).
ALC (@Pharmaceuticals: Other) experienced а +5.91% price change this week, while MDT (@Medical/Nursing Services) price change was +2.55% , and TMO (@Medical Specialties) price fluctuated +6.61% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.24%. For the same industry, the average monthly price growth was +2.18%, and the average quarterly price growth was -11.46%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +1.13%. For the same industry, the average monthly price growth was -2.54%, and the average quarterly price growth was -15.44%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +7.51%. For the same industry, the average monthly price growth was +8.61%, and the average quarterly price growth was +1.13%.
ALC is expected to report earnings on Aug 10, 2026.
MDT is expected to report earnings on Aug 25, 2026.
TMO is expected to report earnings on Jul 29, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (+1.13% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+7.51% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ALC | MDT | TMO | |
| Capitalization | 33.4B | 103B | 183B |
| EBITDA | 2.54B | 9.36B | 11.7B |
| Gain YTD | -13.805 | -15.902 | -14.888 |
| P/E Ratio | 39.03 | 21.25 | 25.51 |
| Revenue | 10.6B | 35.5B | 45.2B |
| Total Cash | 1.66B | 8.38B | 1.12B |
| Total Debt | 5.25B | 28.1B | 43.2B |
ALC | MDT | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 12 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 3 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 89 | |
SMR RATING 1..100 | 89 | 74 | 62 | |
PRICE GROWTH RATING 1..100 | 72 | 59 | 56 | |
P/E GROWTH RATING 1..100 | 49 | 62 | 43 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as TMO (13) in the Medical Specialties industry, and is in the same range as ALC (18) in the Hospital Or Nursing Management industry. This means that MDT's stock grew similarly to TMO’s and similarly to ALC’s over the last 12 months.
TMO's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as MDT (100) in the Medical Specialties industry, and is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that TMO's stock grew similarly to MDT’s and similarly to ALC’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as MDT (74) in the Medical Specialties industry, and is in the same range as ALC (89) in the Hospital Or Nursing Management industry. This means that TMO's stock grew similarly to MDT’s and similarly to ALC’s over the last 12 months.
TMO's Price Growth Rating (56) in the Medical Specialties industry is in the same range as MDT (59) in the Medical Specialties industry, and is in the same range as ALC (72) in the Hospital Or Nursing Management industry. This means that TMO's stock grew similarly to MDT’s and similarly to ALC’s over the last 12 months.
TMO's P/E Growth Rating (43) in the Medical Specialties industry is in the same range as ALC (49) in the Hospital Or Nursing Management industry, and is in the same range as MDT (62) in the Medical Specialties industry. This means that TMO's stock grew similarly to ALC’s and similarly to MDT’s over the last 12 months.
| ALC | MDT | TMO | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 60% | 1 day ago 50% |
| Stochastic ODDS (%) | 1 day ago 57% | 1 day ago 52% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 61% | 1 day ago 59% | 1 day ago 53% |
| MACD ODDS (%) | 2 days ago 60% | 1 day ago 51% | 1 day ago 55% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 56% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 45% | 1 day ago 61% |
| Advances ODDS (%) | 1 day ago 57% | 9 days ago 51% | 1 day ago 62% |
| Declines ODDS (%) | 9 days ago 56% | 17 days ago 58% | 13 days ago 63% |
| BollingerBands ODDS (%) | N/A | 1 day ago 60% | 1 day ago 60% |
| Aroon ODDS (%) | 2 days ago 43% | 1 day ago 55% | 1 day ago 55% |
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.